Back to top
more

Adverum Biotechnologies (ADVM)

(Real Time Quote from BATS)

$7.80 USD

7.80
103,586

+0.15 (1.96%)

Updated Oct 14, 2024 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New Strong Sell Stocks for September 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

Adverum (ADVM) Surges: Stock Moves 6.2% Higher

Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Adverum Biotechnologies (ADVM) Reports Q1 Loss, Lags Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -14.81% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year?

Is (ADVM) Outperforming Other Medical Stocks This Year?

Is Adverum Biotechnologies (ADVM) Outperforming Other Medical Stocks This Year?

Is (ADVM) Outperforming Other Medical Stocks This Year?

Here's Why Momentum Investors Will Love Adverum Biotechnologies (ADVM)

Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.

All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adverum (ADVM): Strong Industry, Solid Earnings Estimate Revisions

Adverum (ADVM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

What Makes Adverum Biotechnologies (ADVM) a New Buy Stock

Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adverum Biotechnologies (ADVM) Reports Q4 Loss, Misses Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 6.45% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Adverum (ADVM)

Adverum (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in the Offing for Ring Energy (REI) Q4 Earnings?

While a substantial ramp-up in output is expected to have driven Ring Energy's (REI) fourth-quarter 2019 earnings, lower commodity prices might dampen its overall results.

The Truth About Market Timing - March 06, 2020

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?

Earnings Preview: Adverum Biotechnologies (ADVM) Q4 Earnings Expected to Decline

Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Keys to Successfully Timing the Markets - February 14, 2020

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Misses Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 7.41% and -47.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

When Does Market Timing Actually Work? - November 04, 2019

Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?